Samlyn Capital LLC Has $12.93 Million Holdings in Corvus Pharmaceuticals, Inc. $CRVS

Key Points

• Samlyn Capital LLC has reduced its stake in Corvus Pharmaceuticals by 39.0%, selling over 2.6 million shares and now holding approximately 4.07 million shares, valued at $12.93 million.
• Barclays PLC and Bank of America Corp DE significantly increased their positions in Corvus Pharmaceuticals, with Barclays increasing holdings by 10,601,800.0% and Bank of America by 23,611.7% in the fourth quarter.
• Corvus Pharmaceuticals' stock is currently trading at $6.16, with a market capitalization of $458.98 million and a consensus target price of $15.00 from several analysts.

Samlyn Capital LLC reduced its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 39.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,065,935 shares of the company's stock after selling 2,601,170 shares during the period. Samlyn Capital LLC owned approximately 5.96% of Corvus Pharmaceuticals worth $12,930,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CRVS. Bank of America Corp DE increased its position in Corvus Pharmaceuticals by 23,611.7% during the 4th quarter. Bank of America Corp DE now owns 96,981 shares of the company's stock worth $519,000 after purchasing an additional 96,572 shares in the last quarter. Barclays PLC boosted its position in shares of Corvus Pharmaceuticals by 10,601,800.0% in the fourth quarter. Barclays PLC now owns 106,019 shares of the company's stock worth $567,000 after buying an additional 106,018 shares during the period. Jump Financial LLC acquired a new stake in Corvus Pharmaceuticals in the first quarter valued at approximately $143,000. Dimensional Fund Advisors LP increased its stake in Corvus Pharmaceuticals by 91.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 22,793 shares of the company's stock worth $122,000 after buying an additional 10,869 shares during the period. Finally, Tower Research Capital LLC TRC acquired a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth about $74,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS stock traded up $0.13 on Thursday, reaching $6.06. 447,224 shares of the company's stock traded hands, compared to its average volume of 788,086. The company has a market capitalization of $451.53 million, a P/E ratio of -6.00 and a beta of 0.52. Corvus Pharmaceuticals, Inc. has a 12-month low of $2.54 and a 12-month high of $10.00. The business's 50 day moving average price is $4.82 and its two-hundred day moving average price is $4.12.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Research analysts predict that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on CRVS shares. Mizuho set a $11.00 price objective on Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. Wall Street Zen upgraded Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Corvus Pharmaceuticals currently has an average rating of "Buy" and an average target price of $15.00.

Insiders Place Their Bets

In other Corvus Pharmaceuticals news, Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the sale, the director directly owned 7,165,006 shares in the company, valued at $29,806,424.96. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 28.50% of the company's stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.